Lowest-Rated StocksLowest-Rated Intercept Pharmaceuticals Stock Price, News & Analysis (NASDAQ:ICPT) $19.00 +0.04 (+0.21%) (As of 11/8/2023) Add Compare Share Share Today's Range$18.98▼$19.0150-Day Range$18.20▼$19.0052-Week Range$8.82▼$21.86Volume3.96 million shsAverage Volume1.36 million shsMarket Capitalization$794.77 millionP/E RatioN/ADividend YieldN/APrice Target$23.18 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Intercept Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingHold2.13 Rating ScoreUpside/Downside22.0% Upside$23.18 Price TargetShort InterestN/ADividend StrengthN/ASustainability-2.13Upright™ Environmental ScoreNews Sentiment0.00Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.04) to $1.93 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.45 out of 5 starsMedical Sector892nd out of 952 stocksBiotechnology Industry26th out of 33 stocks 2.1 Analyst's Opinion Consensus RatingIntercept Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.13, and is based on 1 buy rating, 7 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $23.18, Intercept Pharmaceuticals has a forecasted upside of 22.0% from its current price of $19.00.Amount of Analyst CoverageIntercept Pharmaceuticals has only been the subject of 4 research reports in the past 90 days. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for ICPT. Previous Next 0.0 Dividend Strength Dividend YieldIntercept Pharmaceuticals does not currently pay a dividend.Dividend GrowthIntercept Pharmaceuticals does not have a long track record of dividend growth. Previous Next 3.9 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreIntercept Pharmaceuticals has received a 53.13% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Liver-disease medication (A05)", "Clinical research services for physiological diseases ", and "Basic medical research services" products. See details.Environmental SustainabilityThe Environmental Impact score for Intercept Pharmaceuticals is -2.13. Previous Next 0.0 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 2 news articles for Intercept Pharmaceuticals this week, compared to 3 articles on an average week.MarketBeat FollowsOnly 2 people have added Intercept Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Intercept Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 6.20% of the stock of Intercept Pharmaceuticals is held by insiders.Percentage Held by Institutions83.81% of the stock of Intercept Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Intercept Pharmaceuticals are expected to grow in the coming year, from ($1.04) to $1.93 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Intercept Pharmaceuticals is -12.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Intercept Pharmaceuticals is -12.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioIntercept Pharmaceuticals has a P/B Ratio of 11.05. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Intercept Pharmaceuticals Stock (NASDAQ:ICPT)Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid in adults. It is also developing Ocaliva for various indications, including nonalcoholic steatohepatitis and NASH; and other product candidates in various stages of clinical and preclinical development. The company has a license agreement with Aralez Pharmaceuticals Canada Inc. to develop and commercialize bezafibrate in the United States. It markets its products through an internal commercial organization and third-party distributors. The company was incorporated in 2002 and is headquartered in Morristown, New Jersey. As of November 8, 2023, Intercept Pharmaceuticals, Inc. operates as a subsidiary of Alfasigma S.p.A..Read More ICPT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ICPT Stock News HeadlinesDecember 5, 2023 | americanbankingnews.comIntercept Pharmaceuticals, Inc. (NASDAQ:ICPT) Receives Average Rating of "Hold" from AnalystsNovember 30, 2023 | americanbankingnews.comStockNews.com Initiates Coverage on Intercept Pharmaceuticals (NASDAQ:ICPT)December 5, 2023 | DTI Trader (Ad)New CBOE “special perk” helps traders target income every weekendYou might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange. November 13, 2023 | finance.yahoo.comIntercept Announces New Phase 2 Data Showing Significant Impact of OCA-Bezafibrate Combination on Normalization of Multiple Key Biomarkers of PBC-Induced Liver Damage at AASLD The Liver Meeting® 2023November 10, 2023 | finance.yahoo.comIntercept Announces New Findings from Long-term Extension of Landmark POISE Trial in PBC Showing Importance of Biomarkers Beyond ALP at AASLD The Liver Meeting® 2023November 8, 2023 | finance.yahoo.comAlfasigma S.p.A. successfully completes tender offer for all outstanding shares of common stock of Intercept Pharmaceuticals, Inc.November 2, 2023 | msn.comIntercept Pharmaceuticals (ICPT) Price Target Increased by 6.63% to 19.38October 31, 2023 | finance.yahoo.comWill Intercept Pharmaceuticals (ICPT) Report Negative Q3 Earnings? What You Should KnowDecember 5, 2023 | DTI Trader (Ad)All the trading advice you’ve ever received boils down to thisAll the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.October 27, 2023 | finance.yahoo.comStocks to Sell: 7 Overbought Companies You Ought to Dump Right NowOctober 11, 2023 | finance.yahoo.comIntercept Pharmaceuticals (NASDAQ:ICPT) shareholders have endured a 83% loss from investing in the stock five years agoOctober 5, 2023 | msn.comIntercept Pharmaceuticals (ICPT) Price Target Increased by 21.49% to 18.17September 28, 2023 | msn.comIntercept Pharma unlikely to see rival offers, other roadblocks, analysts saySeptember 28, 2023 | msn.comCanaccord Genuity Downgrades Intercept Pharmaceuticals (ICPT)September 27, 2023 | markets.businessinsider.comIntercept Pharma Acquisition by Alfasigma: A Strategic Move and Fair Value AssessmentSeptember 27, 2023 | proactiveinvestors.comIntercept Pharmaceuticals stock soars on Alfasigma acquisition dealSeptember 26, 2023 | msn.comCanaccord cuts Intercept to hold, calls Alfasigma deal "best possible outcome"September 26, 2023 | benzinga.comShareholder Alert: Ademi LLP investigates whether Intercept Pharmaceuticals, Inc. has obtained a Fair Price in its transaction with AlfasigmaSeptember 26, 2023 | seekingalpha.comIntercept Pharmaceuticals: Alfasigma Pays Premium For M&A Deal That Suits All PartiesSeptember 26, 2023 | investorplace.comWhy Is Intercept Pharmaceuticals (ICPT) Stock Up 75% Today?September 26, 2023 | marketwatch.comIntercept Pharma Shares Surge Toward Alfasigma Acquisition PriceSeptember 26, 2023 | msn.comIntercept Pharmaceuticals’ stock set to soar after Alfasigma buyout deal for an 82% premiumSeptember 26, 2023 | reuters.comItaly's Alfasigma to buy drugmaker Intercept for nearly $800 mlnSeptember 26, 2023 | markets.businessinsider.comAlfasigma To Acquire Intercept Pharma Fo $19 Per Share In CashSeptember 26, 2023 | markets.businessinsider.comWhy Is Rare Liver Disease Focused Intercept Pharmaceuticals Stock Trading Higher Today?September 26, 2023 | finance.yahoo.comAlfasigma to Acquire Intercept Pharmaceuticals for $19.00 per Share in Cash, Expanding the Global Footprint of Alfasigma Via a Leader in Rare and Serious Liver DiseasesSeptember 26, 2023 | finance.yahoo.comUPDATE 2-Italy's Alfasigma to buy US liver disease drugmaker Intercept for nearly $800 mlnSee More Headlines Receive ICPT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Intercept Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/06/2023Today12/04/2023Fiscal Year End12/31/2023Next Earnings (Estimated)3/07/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biotechnology Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:ICPT CUSIP45845P10 CIK1270073 Webwww.interceptpharma.com Phone(646) 747-1000Fax646-747-1001Employees341Year FoundedN/APrice Target and Rating Average Stock Price Target$23.18 High Stock Price Target$54.00 Low Stock Price Target$14.00 Potential Upside/Downside+22.0%Consensus RatingHold Rating Score (0-4)2.13 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($1.48) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$221.82 million Net Margins-19.39% Pretax Margin-18.09% Return on Equity-77.48% Return on Assets-11.99% Debt Debt-to-Equity Ratio3.12 Current Ratio4.22 Quick Ratio2.52 Sales & Book Value Annual Sales$285.71 million Price / Sales2.78 Cash FlowN/A Price / Cash FlowN/A Book Value$1.72 per share Price / Book11.05Miscellaneous Outstanding Shares41,830,000Free Float39,192,000Market Cap$794.77 million OptionableOptionable Beta0.88 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. Jerome B. Durso (Age 55)President, CEO & Director Comp: $1.37MMr. Andrew Saik (Age 54)Chief Financial Officer Comp: $888.6kMr. Jared M. Freedberg J.D. (Age 55)General Counsel Comp: $812.55kMs. Linda M. Richardson (Age 59)Executive VP & Chief Commercial Officer Comp: $837.73kDr. M. Michelle Berrey M.D. (Age 56)M.P.H., President of Research & Development and Chief Medical Officer Comp: $1.12MMr. Rocco Venezia (Age 47)Chief Accounting Officer & Treasurer Comp: $660.62kMr. Nareg SagherianExecutive Director of Global Investor RelationsMr. David Ford (Age 53)Chief Human Resources Officer Comp: $434.9kDr. Mark Pruzanski M.D. (Age 55)Founder, Advisor & Director Comp: $1.3MPaul NitschmannSenior Vice President of Regulatory AffairsMore ExecutivesKey CompetitorsAmicus TherapeuticsNASDAQ:FOLDEQRxNASDAQ:EQRXSage TherapeuticsNASDAQ:SAGEGeneluxNASDAQ:GNLXIovance BiotherapeuticsNASDAQ:IOVAView All CompetitorsInstitutional OwnershipCarmignac GestionBought 85,271 shares on 11/29/2023Ownership: 0.204%Deutsche Bank AGSold 7,744 shares on 11/24/2023Ownership: 0.035%Tudor Investment Corp Et AlBought 115,800 shares on 11/16/2023Ownership: 0.000%GTS Securities LLCBought 13,300 shares on 11/16/2023Ownership: 0.000%Wolverine Trading LLCSold 12,500 shares on 11/16/2023Ownership: 0.000%View All Institutional Transactions ICPT Stock Analysis - Frequently Asked Questions Should I buy or sell Intercept Pharmaceuticals stock right now? 8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Intercept Pharmaceuticals in the last twelve months. There are currently 7 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" ICPT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ICPT, but not buy additional shares or sell existing shares. View ICPT analyst ratings or view top-rated stocks. What is Intercept Pharmaceuticals' stock price target for 2024? 8 analysts have issued 1 year price objectives for Intercept Pharmaceuticals' stock. Their ICPT share price targets range from $14.00 to $54.00. On average, they expect the company's share price to reach $23.18 in the next year. This suggests a possible upside of 22.0% from the stock's current price. View analysts price targets for ICPT or view top-rated stocks among Wall Street analysts. How have ICPT shares performed in 2023? Intercept Pharmaceuticals' stock was trading at $12.37 at the start of the year. Since then, ICPT shares have increased by 53.6% and is now trading at $19.00. View the best growth stocks for 2023 here. When is Intercept Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, March 7th 2024. View our ICPT earnings forecast. How were Intercept Pharmaceuticals' earnings last quarter? Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) announced its quarterly earnings results on Monday, November, 6th. The biopharmaceutical company reported ($0.07) earnings per share for the quarter, topping the consensus estimate of ($0.27) by $0.20. The biopharmaceutical company had revenue of $88.79 million for the quarter, compared to the consensus estimate of $88.02 million. Intercept Pharmaceuticals had a negative net margin of 19.39% and a negative trailing twelve-month return on equity of 77.48%. What ETF holds Intercept Pharmaceuticals' stock ? Virtus LifeSci Biotech Products ETF holds 28,540 shares of ICPT stock, representing 1.65% of its portfolio. What is Mark Pruzanski's approval rating as Intercept Pharmaceuticals' CEO? 32 employees have rated Intercept Pharmaceuticals Chief Executive Officer Mark Pruzanski on Glassdoor.com. Mark Pruzanski has an approval rating of 80% among the company's employees. What other stocks do shareholders of Intercept Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Intercept Pharmaceuticals investors own include Sarepta Therapeutics (SRPT), Gilead Sciences (GILD), Tesla (TSLA), NVIDIA (NVDA), Netflix (NFLX), Alibaba Group (BABA), Micron Technology (MU), Ionis Pharmaceuticals (IONS), Regeneron Pharmaceuticals (REGN) and Biogen (biib). Who are Intercept Pharmaceuticals' major shareholders? Intercept Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional investors include Alpine Associates Management Inc. (5.27%), Hsbc Holdings PLC (1.09%), Acadian Asset Management LLC (0.98%), Northern Trust Corp (0.92%), Versor Investments LP (0.91%) and Rafferty Asset Management LLC (0.73%). Insiders that own company stock include Sandip Kapadia and Srinivas Akkaraju. View institutional ownership trends. How do I buy shares of Intercept Pharmaceuticals? Shares of ICPT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:ICPT) was last updated on 12/5/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Intercept Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.